10,042 Insulet Corporation $PODD Shares Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC grew its position in Insulet Corporation (NASDAQ:PODD) by 91.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,015 shares of the medical instruments supplier’s stock after acquiring an additional 10,042 shares during the period. New York Life Investment Management LLC’s holdings in Insulet were worth $2,742,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PODD. AlphaCore Capital LLC acquired a new stake in Insulet in the third quarter valued at about $557,000. Fulcrum Asset Management LLP boosted its holdings in Insulet by 167.2% in the 3rd quarter. Fulcrum Asset Management LLP now owns 29,236 shares of the medical instruments supplier’s stock valued at $3,884,000 after purchasing an additional 18,293 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Insulet by 7.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,872 shares of the medical instruments supplier’s stock valued at $506,000 after purchasing an additional 263 shares in the last quarter. University of Texas Texas AM Investment Management Co. increased its position in Insulet by 159.3% during the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 630 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 387 shares during the period. Finally, Brighton Jones LLC increased its position in Insulet by 85.0% during the 3rd quarter. Brighton Jones LLC now owns 9,341 shares of the medical instruments supplier’s stock worth $1,219,000 after purchasing an additional 4,292 shares during the period.

Insulet Price Performance

Shares of PODD traded up $3.19 during trading hours on Friday, reaching $152.48. The company had a trading volume of 1,590,709 shares, compared to its average volume of 1,354,922. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The firm has a 50 day simple moving average of $142.14 and a 200-day simple moving average of $173.54. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.14 and a beta of 1.06.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The firm had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm’s revenue was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.24 earnings per share. Research analysts expect that Insulet Corporation will post 6.76 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PODD. Raymond James Financial reissued an “outperform” rating and set a $180.00 target price on shares of Insulet in a research note on Thursday, August 6th. Citigroup raised their price target on Insulet from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Leerink Partners lifted their price target on Insulet from $143.00 to $167.00 and gave the company a “market perform” rating in a research note on Thursday, November 5th. UBS Group upped their price objective on Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Insulet in a report on Wednesday, November 4th. Twelve analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $185.67.

About Insulet

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.